基纳基蛋白激酶抑制剂用于癌症治疗的结构优化的最新进展 (2021年至今)
Heba T Abdel-Mohsen1, Manal M Anwar2, Nesreen S Ahmed2
1Chemistry of Natural and Microbial Products Department, Pharmaceutical and Drug Industries Research Institute, National Research Centre, El-Bohouth Street, Dokki, Cairo P.O. Box 12622, Egypt.
Molecules (Basel, Switzerland)
|February 24, 2024
概括
基纳林衍生物显示出作为向抗癌药物的前景,提供更好的选择性和有效性. 本综述涵盖了针对蛋白质激酶的基纳胺基化疗药物的近期 (2021-2024) 进展.
科学领域:
- 药用化学 医学化学
- 在瘤学瘤学.
- 药物发现 药物发现 药物发现
背景情况:
- 癌症治疗面临的挑战是非选择性,有毒的化疗药物和发展抗药性.
- 针对性治疗对于有效的癌症管理至关重要.
- 基纳佐林支架以其多样化的生物活动和化学多功能性而闻名.
研究的目的:
- 审查最近 (2021-2024) 基纳林衍生物作为抗癌化疗药物.
- 突出其向蛋白激酶和其他分子标的机制.
- 为设计新型quinazoline类似物作为化合物提供见解.
主要方法:
- 从2021-2024年对科学出版物的文献综述.
- 专注于具有已证明抗癌特性的金纳林衍生物.
- 对向蛋白激酶和其他与癌症相关的分子通路的化合物的分析.
主要成果:
- 识别了许多基于quinazoline的化合物,这些化合物表现出显著的抗癌活性.
- 这些衍生物有效地抑制了各种蛋白激酶,这些蛋白质激酶对癌细胞增殖至关重要.
- 最近的研究展示了合成和优化quinazoline支架的进展.
结论:
- 基纳林衍生物代表了一类有前途的向抗癌药物.
- 对quinazoline类似物的持续研究可以导致新的,更有效的癌症疗法.
- 该审查为未来的药物设计和合成策略提供了基础.
相关概念视频
Structure-Activity Relationships and Drug Design
720
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
720
Protein Kinases and Phosphatases
13.1K
Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
13.1K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
M-Cdk Drives Transition Into Mitosis
5.6K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.6K


